Alley Company’s Pfizer PFE Stock Holding History

Alley Company’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-6,515	Closed	-$270K	–	81
2018 Q4	$270K	Buy	+6,515	New	+$270K	0.09%	78

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Alley Company's PFE Position: Q1 2019 in Review

Alley Company sold out of Pfizer (PFE) in Q1 2019, closing a stake of 6,515 shares — an estimated $270K sold.

Alley Company first reported a position in PFE in Q4 2018 and held it in 1 quarter. The position peaked at $270K in Q4 2018. 2,391 funds tracked by Wall St. Rank hold PFE as of Q1 2019.

Alley Company reported no remaining Pfizer position as of Q1 2019 after selling out during the quarter.
Alley Company sold 6,515 Pfizer shares in Q1 2019, an estimated $270K.
Alley Company first reported a position in Pfizer in Q4 2018 and held it in 1 quarter.
Alley Company's Pfizer position peaked at $270K in Q4 2018.
2,391 funds tracked by Wall St. Rank held Pfizer as of Q1 2019.

Based on Alley Company's 13F filing for Q1 2019, filed 6 May 2019.